Cannabis usage in cosmetics

Cannabis and cannabis-derived compounds with a THC concentration of no more than 0.3% (dry weight basis) from the Controlled Substances Act (CSA), which means that these compounds are no longer controlled substances under federal law in Europe. Cannabis and its derivatives, are not cosmetic ingredients prohibited or restricted by regulation. Nevertheless, it must be taken into account that “a product is intended to affect the structure or function of the body, or diagnose, cure, mitigate, treat or prevent disease, it is a drug, or possibly both a cosmetic and a drug, even if it affects the appearance” in accordance with FDA regulations. If a manufacturer would like to have Cannabidiol on its formulation and commercialize the product in the European Union, they should use Cannabidiol which is 100% chemically produced. Moreover, manufacturers must take into account the country of origin of the Cannabis-derived ingredients used and also the tolerance for THC content that has been set out at national level for industrial hemp. In cosmetics, the Responsible Person plays a determinant role safeguarding the compliance of Cannabidiol-containing cosmetic products with regulations and closely monitoring its commercialization across the European Union. These products must not claim having therapeutic effects and should not confuse the public about its cannabis content.